^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NCB-0846

    i
    Other names: NCB 0846, NCB-0846
    Company:
    Carna Biosci, National Cancer Center
    Drug class:
    Wnt signalling pathway inhibitor, TNIK inhibitor
    Related drugs:
    3years
    CRISPR screens identify a novel combination treatment targeting BCL-X and WNT signaling for KRAS/BRAF-mutated colorectal cancers. (PubMed, Oncogene)
    In addition, the combination of ABT-263 and NCB-0846 exhibited synergistic effects in in vivo patient-derived xenograft (PDX) models with KRAS mutations. Our data provide a novel targeted combination treatment strategy for the CRC patient subgroup with KRAS or BRAF mutations.
    Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1)
    |
    KRAS mutation • BRAF mutation • BCL2 expression
    |
    navitoclax (ABT 263) • NCB-0846